Prognosztikai tényezők könnyűlánc-amyloidosisban

dc.contributor.author	Javorniczky NR
dc.contributor.author	Bodó, Imre
dc.contributor.author	Masszi, Tamás
dc.contributor.author	Mikala, Gábor
dc.date.accessioned	2018-09-19T16:38:15Z
dc.date.available	2018-09-19T16:38:15Z
dc.date.issued	2015
dc.identifier	84946091173
dc.identifier.citation	pagination=1577-1584; journalVolume=156; journalIssueNumber=39; journalTitle=ORVOSI HETILAP;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/5910
dc.identifier.uri	doi:10.1556/650.2015.30241
dc.description.abstract	Introduction: Light chain amyloidosis is characterized by extracellular deposition of a fibrillar material derived from immunglobulin light chain fragments. Aim: The aim of the authors was to assess survival depending on cardiac involvement, therapy, and presence of myeloma. Method: The authors studied a retrospective cohort of 29 patients with light chain amyloidosis (13 kappa, 16 lambda) treated in their institution between 2005 and 2014. Results: Twenty-one patients had primary amyloidosis, while 8 had coexisting multiple myeloma. One, two and three or more organs were involved in 4, 8, and 17 patients, respectively. Cardiac involvement (22 cases) inversely correlated with survival. Fifteen (52%) patients received chemotherapy only, while 14 (48%) underwent autologous stem cell transplantation with a median survival of 87 and 11.4 months, respectively. Two patients had heart transplantation and survived 70 and 30 months. Median overall survival was 75.8 months. Conclusions: Cardiac transplantation followed by autologous stem cell transplantation is feasible in selected patients with light chain amyloidosis and heart failure.
dc.relation.ispartof	urn:issn:0030-6002
dc.title	Prognosztikai tényezők könnyűlánc-amyloidosisban
dc.type	Journal Article
dc.date.updated	2018-07-17T13:09:58Z
dc.language.rfc3066	hu
dc.identifier.mtmt	3012986
dc.identifier.wos	000361919500003
dc.identifier.pubmed	26550915
dc.contributor.institution	Semmelweis Egyetem